$FCCO

FIRST COMMUNITY CORP /SC/ (FCCO): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

FIRST COMMUNITY CORP /SC/ (FCCO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective October 1, 2026, the Boards of Directors of First Community Corporation (the “Company”) and First Community Bank

Original reporting
Published Sep 16, 2026, 1:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 1:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$FCCO
Neutral
high confidence
Mentioned
$FCCO
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$FCCONeutralLow
01

Why it matters

The filing provides no new financial data; market reaction is expected to be muted.

02

Market read

Low relevance for traders; primarily a compliance filing.

03

What to watch

Ford's telecom background may influence future technology investments by the bank.

Relevance 6/10Novelty 3/10Timing: effective Oct 1 2026

Background

First Community Corp filed an 8‑K announcing two new directors, a standard corporate governance disclosure.

Company-level read

Ticker impact

$FCCONeutralHigh confidence
Context

SEC 8‑K reports appointment of Terrance Ford and Shell K. Berry as directors of First Community Corp effective Oct 1 2026.

Expected impact

No material price movement expected.

Evidence & confidence

Director appointments are routine and do not alter the company's financial outlook.

Market effects

None

None

None

Counterpoint

Even routine director changes can signal strategic shifts if the appointees bring new expertise.

Key entities

  • Terrance Ford

    Vice President of AT&T South Carolina, appointed director.

  • Shell K. Berry

    President/CEO of Community Foundation for the Central Savannah River Area, appointed director.

Related articles

$FCCOHigh

First Community Corporation Announces Third Quarter Results and Cash Dividend

FIRST COMMUNITY CORP /SC/ (FCCO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 News Release For Release October 21, 2026 9:00 A.M. Contact: Michael C. Crapps, Chief Executive Officer and President D. Shawn Jordan, Executive Vice President & Chief Financial Officer Robin D. Brown, Executive Vice President & Chief Marketing Officer (803) 951-2265

$FCCOMed

Net income rose 54.9% year over year. First Community's margin expanded for a 10th straight quarter.

First Community Corporation (FCCO) reported Q3 2026 net income of $22.1 million, up 54.9% YoY. Diluted EPS rose 26.9% YoY to $4.02. Net interest margin expanded to 3.59%, marking the 10th consecutive quarter of growth. Loans increased by $1.61 billion, with organic growth of $195.7 million. Investment advisory revenue grew 39.9% YoY. The company declared a $0.17 cash dividend.

$FCCOMed

First Community Corporation Announces Leadership Transition, Second Quarter Results and Increased Cash Dividend

FIRST COMMUNITY CORP /SC/ (FCCO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 e26306_ex99-1.htm News Release For Release July 22, 2026 9:00 A.M. Contact: Michael C. Crapps, Chief Executive Officer and President D. Shawn Jordan, Executive Vice President & Chief Financial Officer or Robin D. Brown, Executive Vice President & Chief Marketing Officer

$RCUSHigh

Arcus Biosciences stock falls on public offering announcement

Arcus Biosciences (NYSE:RCUS) shares fell 6.6% in after-hours trading after announcing a public offering of common stock. The company plans to sell shares, with underwriters having a 30-day option for additional shares. Shares had already dropped 20% during regular trading. Citi analyst Yigal Nochomovitz maintained a Buy rating and $50.00 price target, noting clinical trial results met market expectations.